BR112023023813A2 - Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma - Google Patents

Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma

Info

Publication number
BR112023023813A2
BR112023023813A2 BR112023023813A BR112023023813A BR112023023813A2 BR 112023023813 A2 BR112023023813 A2 BR 112023023813A2 BR 112023023813 A BR112023023813 A BR 112023023813A BR 112023023813 A BR112023023813 A BR 112023023813A BR 112023023813 A2 BR112023023813 A2 BR 112023023813A2
Authority
BR
Brazil
Prior art keywords
same
crystalline form
preparing
derivative compound
pharmaceutical composition
Prior art date
Application number
BR112023023813A
Other languages
English (en)
Inventor
John Kim
Gi An Jung
Hyeon Jeon Seong
Original Assignee
Onconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc filed Critical Onconic Therapeutics Inc
Publication of BR112023023813A2 publication Critical patent/BR112023023813A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma. a presente invenção se refere a uma forma cristalina de um citrato de um composto derivado tricíclico representado pela fórmula 1, um método para preparar a forma cristalina do citrato e uma forma cristalina de um composto derivado tricíclico representado pela fórmula 1, utilmente usado na preparação da forma cristalina do citrato.
BR112023023813A 2021-05-18 2022-05-18 Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma BR112023023813A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210064416 2021-05-18
PCT/KR2022/007101 WO2022245125A1 (ko) 2021-05-18 2022-05-18 트리사이클릭 유도체 화합물의 결정형 및 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112023023813A2 true BR112023023813A2 (pt) 2024-02-06

Family

ID=84140601

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023813A BR112023023813A2 (pt) 2021-05-18 2022-05-18 Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma

Country Status (11)

Country Link
EP (1) EP4342898A1 (pt)
JP (1) JP2024519334A (pt)
KR (1) KR20230157374A (pt)
CN (1) CN117321054A (pt)
BR (1) BR112023023813A2 (pt)
CA (1) CA3219303A1 (pt)
CO (1) CO2023015293A2 (pt)
EC (1) ECSP23086661A (pt)
IL (1) IL308326A (pt)
MX (1) MX2023013624A (pt)
WO (1) WO2022245125A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4093448B2 (ja) * 1999-01-11 2008-06-04 アグロン・ファーマシューティカルズ・インコーポレーテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
KR101827444B1 (ko) * 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
CN107849040B (zh) 2015-06-09 2021-04-06 肿瘤学治疗公司 三环衍生化合物、其制备方法、和含有其的药物组合物
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
US9907357B2 (en) 2015-09-24 2018-03-06 Nike, Inc. Fluid-filled chamber for an article of footwear
CN107955001A (zh) * 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐

Also Published As

Publication number Publication date
CN117321054A (zh) 2023-12-29
KR20230157374A (ko) 2023-11-16
IL308326A (en) 2024-01-01
EP4342898A1 (en) 2024-03-27
CA3219303A1 (en) 2022-11-24
CO2023015293A2 (es) 2023-11-20
ECSP23086661A (es) 2023-12-29
JP2024519334A (ja) 2024-05-10
MX2023013624A (es) 2023-11-30
WO2022245125A1 (ko) 2022-11-24

Similar Documents

Publication Publication Date Title
BR112023019797A2 (pt) Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
UY39029A (es) Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
BRPI1016132B8 (pt) composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
AR078507A1 (es) Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion
CL2023000154A1 (es) Proceso para preparar tapinarof; compuestos intermediarios; solvato de tapinarof; forma cristalina y composición farmacéutica que la comprende (sol. div. 202001226).
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
CO2021009261A2 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112022013884A2 (pt) Forma em estado sólido de piroxassulfona
CL2021002263A1 (es) Compuestos antibacterianos (solicitud divisional 202001147)
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
CL2021001869A1 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis.
CY1119710T1 (el) Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CL2023001224A1 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación
BR112023023813A2 (pt) Forma cristalina de composto derivado tricíclico, método para preparar a mesma, e composição farmacêutica que compreende a mesma